1) Moses JW, et al:Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med, 349:1315-1323, 2003
2) Kimura T, et al:Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation:five-year outcome of the j-Cypher Registry. Circulation. 125:584-591, 2012
3) Kimura T, et al:Comparisons of baseline demographics, clinical presentation, and long-term outcome the Registry of Stent Thrombosis for Review and Reevaluation(RESTART). Circulation, 122:52-61, 2010
4) Nakazawa G, et al:Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents. J Am Coll Cardiol, 57:390-398, 2011
5) Nakazawa G, et al:The pathology of neoatherosclerosis in human coronary implants bare-metal and drugeluting stents. J Am Coll Cardiol, 57:1314-1322, 2011
6) Imai M, et al:Incidence, risk factors, and clinical sequelae of angiographic peri-stent contrast staining after sirolimus-eluting stent implantation. Circulation, 123:2382-2391, 2011
7) Natsuaki M, et al:Late adverse events after implantation of sirolimus-eluting stent and bare-metal stent:long-term(5-7 years)follow-up of the Coronary Revascularization Demonstrating Outcome study-Kyoto registry Cohort-2. Circ Cardiovasc Interv, 7:168-179, 2014
8) Kim JS, et al:Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography:the ENDEAVOR OCT trial. J Am Coll Cardiol Intv, 2:1240-1247, 2009
9) Awata M, et al:Angioscopic comparison of neointimal coverage between zotarolimus- and sirolimus-eluting stents. J Am Coll Cardiol, 52:789-790, 2008
10) Ishihara T, et al:Arterial repair 4 months after zotarolimus-eluting stent implantation observed on angioscopy. Circ J, 77:1186-1192, 2013
11) Tada T, et al:Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents:results from a registry of 18,334 patients. J Am Coll Cardiol Intv, 6:1267-1274, 2013
12) Sabate M, et al:Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction(EXAMINATION):1 year results of a randomised controlled trial. Lancet, 380:1482-1490, 2012
13) Kolandaivelu K, et al:Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation, 123:1400-1409, 2011
14) Otsuka F, et al:Pathology of second-generation everolimus-eluting stents versus first-generation sirolimusand paclitaxel-eluting stents in humans. Circulation, 129:211-223, 2014
15) Urban P, et al:Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med, 373:2038-2047, 2015
16) Kandzari DE, et al:Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation(BIOFLOW V):a randomised trial. Lancet, 390:1843-1852, 2017
17) 「循環器病の診断と治療に関するガイドライン:安定冠動脈疾患における待機的PCIのガイドライン(2011年改訂版)」(2010年度合同研究班報告) http://www.j-circ.or.jp/guideline/pdf/JCS2011_fujiwara_h.pdf
18) Levine GN, et al:2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. Circulation, 134:e123-e155, 2016
19) Valgimigli M, et al:2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J, 39:213-260, 2018
20) Farid NA, et al:Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol, 50:126-142, 2010